The transaction is sourced from an 8-K filing with the SEC, filed via SEC EDGAR and published on April 24, 2023. The deal's current status is pending regulatory approval.
On the financial advisory side, J.P. Morgan Securities LLC acted as financial advisor to Lilly, the target/divesting party, in a lead capacity. Jefferies LLC acted as financial advisor to Amphastar, the acquirer, also in a lead capacity, with each advisor paired with its respective legal counsel in the source material.
On the legal side, two firms represented Lilly (the target/divesting party): Kirkland & Ellis LLP and Covington & Burling LLP, both named as legal counsel in the same source sentence as J.P. Morgan's role. Wilson, Sonsini, Goodrich & Rosati, P.C. represented Amphastar, the acquirer, as legal counsel.
Beyond the cash consideration for this asset divestiture, with a disclosed deal value of $625,000,000, no further detail on specific terms of the asset transfer beyond it being a product/asset acquisition is provided in the facts block.
Several items are not disclosed in the available record. No further structural detail beyond the asset divestiture and cash acquisition classification is given, and no expected closing date or further timeline detail beyond the April 2023 filing date and pending-regulatory status is provided.